Los lípidos activan un eje riñón-cerebro GDF15 para suprimir la ingesta de alimentos

Ameth N Garrido1,2, Song-Yang Zhang1, Kyla Bruce1,3

  • 1Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.

Diabetes
|August 28, 2025
PubMed
Resumen

La infusión de lípidos del intestino delgado superior afecta el factor de diferenciación de crecimiento 15 (GDF15) y la ingesta de alimentos de manera diferente en ratas en función de la dieta. El riñón GDF15 y el área postrema GFRAL son clave en la mediación de estos efectos inducidos por los lípidos.

Videos de Conceptos Relacionados

Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
350
Glomerular Filtration Rate and its Regulation01:28

Glomerular Filtration Rate and its Regulation

The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
3.3K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416